![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: PGD |
Gene summary for PGD |
![]() |
Gene information | Species | Human | Gene symbol | PGD | Gene ID | 5226 |
Gene name | phosphogluconate dehydrogenase | |
Gene Alias | 6PGD | |
Cytomap | 1p36.22 | |
Gene Type | protein-coding | GO ID | GO:0005975 | UniProtAcc | B4E2U0 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
5226 | PGD | HTA11_347_2000001011 | Human | Colorectum | AD | 9.16e-03 | 2.31e-01 | -0.1954 |
5226 | PGD | HTA11_696_2000001011 | Human | Colorectum | AD | 6.10e-10 | 4.15e-01 | -0.1464 |
5226 | PGD | HTA11_1391_2000001011 | Human | Colorectum | AD | 2.34e-12 | 6.96e-01 | -0.059 |
5226 | PGD | HTA11_866_3004761011 | Human | Colorectum | AD | 2.32e-06 | 4.39e-01 | 0.096 |
5226 | PGD | HTA11_8622_2000001021 | Human | Colorectum | SER | 3.11e-03 | 4.52e-01 | 0.0528 |
5226 | PGD | HTA11_7696_3000711011 | Human | Colorectum | AD | 5.78e-08 | 3.88e-01 | 0.0674 |
5226 | PGD | HTA11_99999970781_79442 | Human | Colorectum | MSS | 5.57e-10 | 4.43e-01 | 0.294 |
5226 | PGD | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 1.28e-02 | 1.12e+00 | 0.3487 |
5226 | PGD | HTA11_99999965104_69814 | Human | Colorectum | MSS | 4.70e-07 | 5.78e-01 | 0.281 |
5226 | PGD | HTA11_99999971662_82457 | Human | Colorectum | MSS | 4.90e-27 | 8.09e-01 | 0.3859 |
5226 | PGD | HTA11_99999973899_84307 | Human | Colorectum | MSS | 2.93e-07 | 6.18e-01 | 0.2585 |
5226 | PGD | HTA11_99999974143_84620 | Human | Colorectum | MSS | 5.05e-04 | 2.23e-01 | 0.3005 |
5226 | PGD | LZE2D | Human | Esophagus | HGIN | 4.04e-03 | 1.06e+00 | 0.0642 |
5226 | PGD | LZE2T | Human | Esophagus | ESCC | 4.35e-14 | 2.58e+00 | 0.082 |
5226 | PGD | LZE4T | Human | Esophagus | ESCC | 9.90e-46 | 2.85e+00 | 0.0811 |
5226 | PGD | LZE7T | Human | Esophagus | ESCC | 1.16e-26 | 2.42e+00 | 0.0667 |
5226 | PGD | LZE8T | Human | Esophagus | ESCC | 1.17e-05 | 4.94e-01 | 0.067 |
5226 | PGD | LZE20T | Human | Esophagus | ESCC | 4.81e-11 | 1.04e+00 | 0.0662 |
5226 | PGD | LZE22D1 | Human | Esophagus | HGIN | 2.27e-10 | 1.16e+00 | 0.0595 |
5226 | PGD | LZE22T | Human | Esophagus | ESCC | 5.71e-13 | 2.26e+00 | 0.068 |
Page: 1 2 3 4 5 6 7 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000223713 | Cervix | HSIL_HPV | response to molecule of bacterial origin | 36/737 | 363/18723 | 3.74e-07 | 2.06e-05 | 36 |
GO:003249613 | Cervix | HSIL_HPV | response to lipopolysaccharide | 34/737 | 343/18723 | 7.95e-07 | 3.94e-05 | 34 |
GO:003235513 | Cervix | HSIL_HPV | response to estradiol | 18/737 | 141/18723 | 1.09e-05 | 3.69e-04 | 18 |
GO:004645611 | Cervix | HSIL_HPV | icosanoid biosynthetic process | 10/737 | 56/18723 | 5.80e-05 | 1.40e-03 | 10 |
GO:000717913 | Cervix | HSIL_HPV | transforming growth factor beta receptor signaling pathway | 20/737 | 198/18723 | 1.12e-04 | 2.33e-03 | 20 |
GO:000151611 | Cervix | HSIL_HPV | prostaglandin biosynthetic process | 7/737 | 31/18723 | 1.64e-04 | 3.14e-03 | 7 |
GO:004645711 | Cervix | HSIL_HPV | prostanoid biosynthetic process | 7/737 | 31/18723 | 1.64e-04 | 3.14e-03 | 7 |
GO:00066927 | Cervix | HSIL_HPV | prostanoid metabolic process | 8/737 | 49/18723 | 5.99e-04 | 8.37e-03 | 8 |
GO:00066937 | Cervix | HSIL_HPV | prostaglandin metabolic process | 8/737 | 49/18723 | 5.99e-04 | 8.37e-03 | 8 |
GO:0019372 | Cervix | HSIL_HPV | lipoxygenase pathway | 4/737 | 11/18723 | 6.30e-04 | 8.64e-03 | 4 |
GO:007156013 | Cervix | HSIL_HPV | cellular response to transforming growth factor beta stimulus | 21/737 | 250/18723 | 9.34e-04 | 1.18e-02 | 21 |
GO:007155913 | Cervix | HSIL_HPV | response to transforming growth factor beta | 21/737 | 256/18723 | 1.26e-03 | 1.48e-02 | 21 |
GO:000717813 | Cervix | HSIL_HPV | transmembrane receptor protein serine/threonine kinase signaling pathway | 26/737 | 355/18723 | 1.86e-03 | 1.97e-02 | 26 |
GO:00486611 | Cervix | HSIL_HPV | positive regulation of smooth muscle cell proliferation | 11/737 | 104/18723 | 2.62e-03 | 2.53e-02 | 11 |
GO:00065755 | Cervix | HSIL_HPV | cellular modified amino acid metabolic process | 16/737 | 188/18723 | 3.18e-03 | 2.89e-02 | 16 |
GO:00066907 | Cervix | HSIL_HPV | icosanoid metabolic process | 12/737 | 123/18723 | 3.36e-03 | 3.04e-02 | 12 |
GO:00067495 | Cervix | HSIL_HPV | glutathione metabolic process | 8/737 | 64/18723 | 3.51e-03 | 3.15e-02 | 8 |
GO:00066362 | Cervix | HSIL_HPV | unsaturated fatty acid biosynthetic process | 7/737 | 51/18723 | 3.65e-03 | 3.25e-02 | 7 |
GO:004866012 | Cervix | HSIL_HPV | regulation of smooth muscle cell proliferation | 15/737 | 180/18723 | 5.11e-03 | 4.14e-02 | 15 |
GO:004865912 | Cervix | HSIL_HPV | smooth muscle cell proliferation | 15/737 | 184/18723 | 6.24e-03 | 4.86e-02 | 15 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa01200 | Colorectum | AD | Carbon metabolism | 55/2092 | 115/8465 | 5.53e-08 | 8.42e-07 | 5.37e-07 | 55 |
hsa00480 | Colorectum | AD | Glutathione metabolism | 23/2092 | 57/8465 | 6.52e-03 | 2.76e-02 | 1.76e-02 | 23 |
hsa012001 | Colorectum | AD | Carbon metabolism | 55/2092 | 115/8465 | 5.53e-08 | 8.42e-07 | 5.37e-07 | 55 |
hsa004801 | Colorectum | AD | Glutathione metabolism | 23/2092 | 57/8465 | 6.52e-03 | 2.76e-02 | 1.76e-02 | 23 |
hsa012002 | Colorectum | SER | Carbon metabolism | 40/1580 | 115/8465 | 2.77e-05 | 3.41e-04 | 2.47e-04 | 40 |
hsa012003 | Colorectum | SER | Carbon metabolism | 40/1580 | 115/8465 | 2.77e-05 | 3.41e-04 | 2.47e-04 | 40 |
hsa012004 | Colorectum | MSS | Carbon metabolism | 43/1875 | 115/8465 | 1.37e-04 | 1.17e-03 | 7.19e-04 | 43 |
hsa004802 | Colorectum | MSS | Glutathione metabolism | 22/1875 | 57/8465 | 3.58e-03 | 1.64e-02 | 1.01e-02 | 22 |
hsa012005 | Colorectum | MSS | Carbon metabolism | 43/1875 | 115/8465 | 1.37e-04 | 1.17e-03 | 7.19e-04 | 43 |
hsa004803 | Colorectum | MSS | Glutathione metabolism | 22/1875 | 57/8465 | 3.58e-03 | 1.64e-02 | 1.01e-02 | 22 |
hsa0120016 | Esophagus | HGIN | Carbon metabolism | 31/1383 | 115/8465 | 2.51e-03 | 2.10e-02 | 1.67e-02 | 31 |
hsa0120017 | Esophagus | HGIN | Carbon metabolism | 31/1383 | 115/8465 | 2.51e-03 | 2.10e-02 | 1.67e-02 | 31 |
hsa0048018 | Esophagus | ESCC | Glutathione metabolism | 44/4205 | 57/8465 | 1.81e-05 | 9.03e-05 | 4.63e-05 | 44 |
hsa0120023 | Esophagus | ESCC | Carbon metabolism | 79/4205 | 115/8465 | 2.50e-05 | 1.21e-04 | 6.22e-05 | 79 |
hsa0048019 | Esophagus | ESCC | Glutathione metabolism | 44/4205 | 57/8465 | 1.81e-05 | 9.03e-05 | 4.63e-05 | 44 |
hsa0120033 | Esophagus | ESCC | Carbon metabolism | 79/4205 | 115/8465 | 2.50e-05 | 1.21e-04 | 6.22e-05 | 79 |
hsa0120021 | Liver | Cirrhotic | Carbon metabolism | 64/2530 | 115/8465 | 6.37e-09 | 1.18e-07 | 7.26e-08 | 64 |
hsa004809 | Liver | Cirrhotic | Glutathione metabolism | 30/2530 | 57/8465 | 2.63e-04 | 1.72e-03 | 1.06e-03 | 30 |
hsa0120031 | Liver | Cirrhotic | Carbon metabolism | 64/2530 | 115/8465 | 6.37e-09 | 1.18e-07 | 7.26e-08 | 64 |
hsa0048012 | Liver | Cirrhotic | Glutathione metabolism | 30/2530 | 57/8465 | 2.63e-04 | 1.72e-03 | 1.06e-03 | 30 |
Page: 1 2 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PGD | SNV | Missense_Mutation | c.868N>G | p.Leu290Val | p.L290V | P52209 | protein_coding | tolerated(0.08) | probably_damaging(0.924) | TCGA-AN-A0G0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
PGD | SNV | Missense_Mutation | c.862N>T | p.Arg288Trp | p.R288W | P52209 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BH-A1EV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | |
PGD | deletion | Frame_Shift_Del | novel | c.14delA | p.Asp5AlafsTer4 | p.D5Afs*4 | P52209 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
PGD | SNV | Missense_Mutation | c.442N>C | p.Glu148Gln | p.E148Q | P52209 | protein_coding | tolerated(0.14) | benign(0.013) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD | |
PGD | SNV | Missense_Mutation | c.863N>A | p.Arg288Gln | p.R288Q | P52209 | protein_coding | deleterious(0.04) | probably_damaging(0.911) | TCGA-DS-A1OD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | |
PGD | SNV | Missense_Mutation | c.126C>A | p.Phe42Leu | p.F42L | P52209 | protein_coding | deleterious(0.03) | probably_damaging(1) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
PGD | SNV | Missense_Mutation | novel | c.256G>C | p.Glu86Gln | p.E86Q | P52209 | protein_coding | tolerated(0.12) | benign(0.007) | TCGA-VS-A958-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
PGD | SNV | Missense_Mutation | c.759N>T | p.Lys253Asn | p.K253N | P52209 | protein_coding | deleterious(0.04) | possibly_damaging(0.495) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
PGD | SNV | Missense_Mutation | c.1222C>T | p.Arg408Trp | p.R408W | P52209 | protein_coding | deleterious(0) | possibly_damaging(0.884) | TCGA-AD-6964-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | folfox | PD | |
PGD | SNV | Missense_Mutation | c.137A>G | p.Glu46Gly | p.E46G | P52209 | protein_coding | deleterious(0.03) | benign(0.305) | TCGA-AZ-6601-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5226 | PGD | ENZYME, DRUGGABLE GENOME | PENICILLAMINE | PENICILLAMINE | 289317 | |
5226 | PGD | ENZYME, DRUGGABLE GENOME | GHRP-2 | |||
5226 | PGD | ENZYME, DRUGGABLE GENOME | PHENOBARBITAL | PHENOBARBITAL | 7827108 |
Page: 1 |